An Open-Label, Single Arm Study to Evaluate the Efficacy and Safety of REGN3918 in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) Who Are Complement Inhibitor-Naive or Have Not Recently Received Complement Inhibitor Therapy
Phase of Trial: Phase II
Latest Information Update: 25 Nov 2019
Price : $35 *
At a glance
- Drugs Pozelimab (Primary) ; Pozelimab (Primary)
- Indications Paroxysmal nocturnal haemoglobinuria
- Focus Therapeutic Use
- Sponsors Regeneron Pharmaceuticals
- 20 Nov 2019 Planned End Date changed from 21 Jun 2021 to 17 May 2021.
- 20 Nov 2019 Planned primary completion date changed from 1 Jun 2021 to 26 Apr 2021.
- 11 Jun 2019 Planned End Date changed from 7 Jul 2021 to 21 Jun 2021.